PEEL Therapeutics

PEEL Therapeutics is a clinical-stage biotechnology company based in Salt Lake City, Utah, in the United States. The company describes itself as "evolutionary-inspired," meaning that it searches the natural world for biological "outliers" — organisms or biological mechanisms that have evolved unusual abilities to resist or circumvent disease — and then translates those abilities into new medicines. Its stated mission is to transform nature into medicines for patients with cancer and immune diseases, a concept it summarizes with the phrase "Transcending the incremental." The company's therapeutic focus is on cancer and inflammation, with a pipeline that it describes as treating a spectrum of devastating conditions. Its lead disclosed program is PEEL-224, a TOP1 inhibitor, which the company has presented at scientific meetings including the Connective Tissue Oncology Society Annual Meeting and the Society for Immunotherapy of Cancer Annual Meeting. PEEL Therapeutics has also reported research findings related to excessive NETosis induction in Long COVID, reflecting an interest in immune and inflammatory mechanisms beyond oncology. As a clinical-stage biotech, PEEL Therapeutics is privately held and has raised financing from investors. In February 2023 the company announced that it had closed a new financing round and expanded its board of directors to support its evolution-based medicine strategy. The company maintains an active news and events section on its website and engages with the scientific and clinical communities through conference presentations and publications. PEEL Therapeutics operates in the biotechnology sector within the broader health care and pharmaceutical industries. Its headquarters in Salt Lake City places it within the United States' life sciences ecosystem, and its work sits at the intersection of evolutionary biology, drug discovery, and clinical development. The company's public communications emphasize its scientific platform and pipeline rather than consumer products, consistent with its identity as a research-driven biopharmaceutical company.

PEEL Therapeutics is a biotechnology company headquartered in Salt Lake City, Utah, United States. The company was founded to pursue an "evolutionary-inspired" approach to drug discovery, based on the idea that millions of years of natural selection have produced organisms and biological mechanisms with extraordinary abilities to resist or circumvent disease. PEEL Therapeutics seeks to identify these "evolutionary outliers" and translate their biology into medicines for patients with cancer and inflammatory diseases. The company has positioned itself as a clinical-stage biotech, indicating that at least one of its therapeutic candidates has advanced into human testing. Its disclosed lead program is PEEL-224, a TOP1 inhibitor. TOP1 inhibitors are a class of anticancer agents that interfere with the enzyme topoisomerase I, which is involved in DNA replication and transcription. PEEL Therapeutics has presented data on PEEL-224 at major scientific conferences, including the Connective Tissue Oncology Society Annual Meeting and the Society for Immunotherapy of Cancer Annual Meeting, as announced in November 2023. Beyond oncology, PEEL Therapeutics has investigated immune and inflammatory mechanisms. In April 2023, the company reported findings on excessive NETosis induction in Long COVID. NETosis is a form of programmed cell death in neutrophils that releases web-like structures called neutrophil extracellular traps (NETs); excessive NETosis has been implicated in various inflammatory and thrombotic conditions. This research aligns with the company's stated focus on cancer and inflammation. In February 2023, PEEL Therapeutics announced that it had closed a new financing round and expanded its board of directors to support its evolution-based medicine strategy. The company continues to operate as a private, clinical-stage biotechnology company, engaging with the scientific community through conference presentations and news updates on its website. Its headquarters in Salt Lake City places it within the growing life sciences cluster in Utah.

• PEEL Therapeutics closes a new financing round and expands its board of directors to support evolution-based medicine.

• PEEL Therapeutics reports excessive NETosis induction in Long COVID.

• PEEL Therapeutics announces it will present data on its TOP1 inhibitor PEEL-224 at the Connective Tissue Oncology Society Annual Meeting and the Society for Immunotherapy of Cancer Annual Meeting.

Clinical-stage, evolutionary-inspired biotechnology company developing medicines for cancer and inflammatory diseases.

• PEEL-224

  A TOP1 inhibitor in clinical development for cancer, presented at scientific meetings including the Connective Tissue Oncology Society Annual Meeting and the Society for Immunotherapy of Cancer Annual Meeting.

1. 1Peel Therapeutics | Transcending the incrementalpeeltx.com
2. 2About | Peel Therapeuticspeeltx.com
3. 3PEEL Therapeutics (United States) - Wikidatawikidata.org